a loss of $48.5 million in its third quarter. The Redwood City, California-based company said it had a loss of $1.24 per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.14 per share. Heron Therapeutics shares have decreased 40 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $16.10, a fall of 43 percent in the last 12 months.
